Marker Therapeutics, Inc. (MRKR) Dividend History

Marker Therapeutics, Inc. is a biotechnology company focused on the development of targeted T-cell therapies for cancer. Utilizing its proprietary MultiVax platform, the company designs and manufactures personalized immunotherapies aimed at activating the patient's immune system to fight various cancers. Founded to advance innovative cancer treatment options, Marker Therapeutics aims to improve outcomes for patients with difficult-to-treat tumors.

2450 Holcombe Blvd, Houston, TX, 77021
Phone: (713) 400-6400
Website: http//www.markertherapeutics.com

Dividend History

Marker Therapeutics, Inc. currently does not pay dividends

Company News

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics, a clinical-stage immuno-oncology company, announced that its President and CEO will present at the Citizens JMP Hematology and Oncology Summit on December 2, 2024. The presentation will provide an overview of the company's technology and clinical developments.

GlobeNewswire Inc.
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study

GlobeNewswire Inc.
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada

GlobeNewswire Inc.
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse

GlobeNewswire Inc.
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 20:57:17 UTC